Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050007/S049

StarClose SE Vascular Closure System

Abbott Vascular Devices · Decision date Apr 17, 2026

FDA DECISIONP050007/S049

What did the FDA decide?

FDA records P050007/S049 as a supplement to PMA P050007, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 17, 2026.

FDA approval order statement

implementation of the sustainable ethylene oxide (SEO) cycle in Chamber 1 and Chamber 2 at Sterigenics UK
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Apr 17, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P050007/S049
Regulatory pathway
PMA supplement
Product code
MGB
Decision code
OK30
Decision date
Apr 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, hemostasis, vascular.

Product code
MGB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P050007/S047 · Related supplement

    StarClose SE Vascular Surgical System

  2. P050007/S048 · Related supplement

    StarClose SE Vascular Closure System

  3. P050007/S049 received

    Application receipt date recorded by FDA.

  4. P050007/S049 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P050007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050007

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott Vascular DevicesPMA supplementDec 9, 2025FDA
Abbott Vascular DevicesPMA supplementMar 2, 2026FDA

Explore the linked device profile

Other records with product code MGB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Vascular Devices

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records